Our Values
Respecting healthy life
Creating & sharing knowledge
Committing to trust & quality
Founded by the leaders
in Lynch syndrome research
Lynsight has been on the forefront of Lynch syndrome research for over 10 years, driven by the mission to find a better way to help people prevent cancer. What started in the labs of the University of Helsinki in the 1990s will not stop until every potential Lynch syndrome case is tested every year.
Bringing preventative care to
more families
Every Lynch syndrome case that remains unclear is an entire family that could be missing out on life saving cancer preventative strategies. Lynsight is dedicated to making sure these families become known and cared for by testing for Lynch syndrome early.
ABOUT LYNCH
SYNDROME
Lynch syndrome is the main cause of hereditary cancers with a broad spectrum of tumors, the most prominent being colorectal and endometrial cancers. With an estimated 1 in 300 people of the world’s population being affected by Lynch syndrome, there are millions of people at a very increased risk for cancer.
Founding Year
Lynsight is founded (as LS CancerDiag) as a spin-off from the University of Helsinki, also thanks to an ERC grant.
2013
First Patent Granted
Australia is the first country to grant the patent to Lynsight for the DiagMMR innovation.
2015
First Validation Study
A first clinical study is launched to validate DiagMMR in collaboration with the central hospitals of Helsinki and Jyväskylä.
2016
Validation Study Results
The validation study is complete with excellent accuracy results.
2018
Domestic Market Launch
DiagMMR obtains the CE mark and is launched into the Finnish market (ceased in 2023).
2019
International Attention
Lynsight is selected for various accelerator programmes across Europe to support the new phase of growth.
2020
ISO Certification
Lynsight's Quality Management System is certified according to the international ISO 13485 standard for medical devices.
2022
Fundraising of €5.4M
Lynsight successfully raises funds in record time to establish operations in the US and fuel the growth ambitions into this key market.
2023
Strategic Rebrand
Lynsight rebrands itself in preparation for the strategic priority of entering the US market.
2024
The future of
Lynch syndrome testing
Lynsight’s purpose is to improve global health outcomes by providing reliable diagnostics for Lynch syndrome and promoting awareness about hereditary cancer risks. With a commitment to pushing the boundaries of scientific discovery, we’re leading the way toward a future where Lynch syndrome testing is not only more accessible but also more precise and impactful.